• Publications
  • Influence
Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial.
TLDR
Dienogest 2 mg/day orally demonstrated equivalent efficacy to depot LA at standard dose in relieving the pain associated with endometriosis, although offering advantages in safety and tolerability. Expand
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
TLDR
EE 20 microg/DRSP 3 mg has a good safety profile comparable with EE 20microg/DSG 150 microg, and the differences in lipid, hemostatic or carbohydrate parameters were not significant between the two treatments. Expand
Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis
To analyze the secondary efficacy and safety outcomes from a recent trial comparing dienogest (DNG) with leuprolide acetate (LA) in women with endometriosis.
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
TLDR
The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication. Expand
Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled
TLDR
The 3 mg drsp/20 mcg EE 24/4 regimen COC was well tolerated and had a safety profile consistent with low-dose COC use. Expand
Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
TLDR
EE/DRSP in a flexible extended regimen with management of intracyclic (breakthrough) bleeding is well-tolerated and, when administered for up to 2 years, has a good safety profile comparable to other estrogen/progestogen oral contraceptives. Expand
Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
TLDR
The drsp 3 mg/EE 20 mcg oral contraceptive in a 24/4 regimen was associated with greater ovarian suppression (despite intentional dosing error), which results in decreased hormonal fluctuations, and may increase contraceptive efficacy with the low-dose formulation. Expand
A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion
TLDR
The COC 3-mg DRSP/20-microg EE 24/4 regimen COC is a suitable option for women with moderate acne vulgaris who require contraception. Expand
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
TLDR
The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication. Expand
A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20μg and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20μg and Desogestrel 150μg
TLDR
Overall, cycle control, efficacy, and safety profiles were comparable between both groups, and both ethinylestradiol 20μg/drospirenone 3mg and ethinylestrozine 20 μg/desogestrel 150μg are effective and well tolerated contraceptives that provide good cycle control. Expand
...
1
2
3
4
...